CASP1 and atherosclerosis: Moreover, VX-765 has demonstrated inhibition of the harmful death of vascular smooth muscle cells (VSMCs) in atherosclerosis, indicating that targeting caspase-1 activity could be a promising therapeutic approach for atherosclerotic cardiovascular diseases [32].